CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

Published:2013-06 Issue:7 Volume:14 Page:590-598
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Seto Takashi,Kiura Katsuyuki,Nishio Makoto,Nakagawa Kazuhiko,Maemondo Makoto,Inoue Akira,Hida Toyoaki,Yamamoto Nobuyuki,Yoshioka Hiroshige,Harada Masao,Ohe Yuichiro,Nogami Naoyuki,Takeuchi Kengo,Shimada Tadashi,Tanaka Tomohiro,Tamura Tomohide

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. A mouse model for EML4-ALK-positive lung cancer;Soda;Proc Natl Acad Sci,2008

3. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy;Webb;Expert Rev Anticancer Ther,2009

4. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma;Christensen;Mol Cancer Ther,2007

5. ROS1 rearrangements define a unique molecular class of lung cancers;Bergethon;J Clin Oncol,2012

Cited by 522 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study;JTO Clinical and Research Reports;2024-09

2. Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies;Cancers;2024-08-06

3. Nephrotoxicity of targeted therapy used to treat lung cancer;Frontiers in Immunology;2024-07-04

4. Solubility, pH-Solubility Profile, pH-Rate Profile, and Kinetic Stability of the Tyrosine Kinase Inhibitor, Alectinib;Pharmaceuticals;2024-06-13

5. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies;Cancer Drug Resistance;2024-05-23